JANX
Janux Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.24
+2.22%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.48
- Revenue estimate
- $8.0M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.35
- EPS estimate
- -$0.25
- Revenue actual
- $10.3M
- Revenue estimate
- $19.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +1.5%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $39
- PT range
- $23 – $55
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026